Midomafetamine

Police in the Netherlands found a 2kg MDMA garden gnome during a drug bust, leading to humorous remarks about the gnome's startled expression.

Kalesi Volatabu, Founder of Drug Free World Fiji, warns that Fiji’s drug crisis has escalated with users openly sharing illicit substances. The crisis extends beyond traditional drugs like crystal meth and heroin to include LSD, ecstasy, and ketamine. Volatabu emphasizes the urgent need for action and open dialogue to address the issue.

The FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy for PTSD highlights the need for consistent clinical trial outcomes. Psychedelics show potential for rapid-acting benefits but require proof of lasting impact. Future research will refine treatments, focusing on safety and long-term efficacy. The regulatory landscape may shift towards drug-therapy combinations, necessitating collaboration between the FDA and professional organizations. NIDA's funding of a ketamine study signals a positive shift in regulatory attitudes towards psychedelics. Each psychedelic compound has unique properties suited for specific conditions, with MDMA for PTSD and psilocybin for depression showing promise. Further research is needed to determine the longevity of therapeutic effects. Challenges in conducting psychedelic trials include safety screening and regulatory navigation, which can be addressed through rigorous trial design and collaboration.

After years of delays, FDA approves Phase 2 of MAPS' study on smoked medical marijuana for PTSD in veterans, funded by Michigan's cannabis tax revenue.

Colorado finalizes pioneering psychedelic-assisted therapy program regulations, with two facilitator licensing tracks, closely watched as a national model. The state will regulate natural medicines, with DORA overseeing training and licensing, and the Department of Revenue managing cultivation, manufacture, and testing. Local communities are establishing rules for the new industry, with some considering temporary moratoriums. High fees and costs of licensing pose challenges for practitioners.

Robert F. Kennedy Jr. criticizes FDA's suppression of non-patentable health products, including psychedelics, stem cells, raw milk, and vitamins, suggesting he may permit unapproved medical products and marketing claims, prohibit certain food additives, and allow interstate shipment of raw milk if appointed to HHS secretary.

Robert F. Kennedy Jr. criticizes FDA's suppression of non-patentable health products, suggesting changes to approval processes, marketing claims, and food regulations if appointed to HHS secretary.

Scientists fear Trump's administration could undermine public health achievements, with Robert F. Kennedy Jr. potentially leading a radical antiestablishment movement. Vaccine mandates, new vaccine approvals, and FDA decisions could be impacted, along with potential mass firings of dissenting scientists. Kennedy and allies advocate for dramatic public health changes, criticizing government agencies for promoting unhealthy practices and dangerous drugs. The potential for significant changes in federal health agencies, including the NIH and CDC, is concerning to many health professionals.

A drug dealer, Jordan McCourt-Knight, lost a bag of ketamine on a train, reported it missing, and inadvertently led to the collapse of a criminal organization. The British Transport Police found the bag, arrested McCourt-Knight, and used his EncroPhone to trace his employer, Harley Hall. Both were convicted and sentenced to prison.

CaaMTech received regulatory approval for its functional unblinding strategy in CT-4201 drug trials, addressing a major hurdle in psychedelic medicine development.